FINWIRES · TerminalLIVE
FINWIRES

$JAZZ

12 stories mentioning JAZZUpdated 19d ago

Every FINWIRES story that references JAZZ, newest first.

Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says

Jazz Pharmaceuticals (JAZZ) is unlikely to see a meaningful Q2-driven stock reaction, with investors focused instead on the expected approval and launch of Ziihera in gastroesophageal adenocarcinoma, or GEA, as the key near-term catalyst, UBS said in a note Wednesday.The analysts said that while the stock has lagged the recent biotech rally, this is largely because gains have been concentrated in smaller-cap companies driven by mergers and acquisitions activity, and some investors had already expected National Comprehensive Cancer Network guideline inclusion for GEA, which has yet to occur."We note that Jazz stock outperformed in Q4 2025/Q1 2026, but we believe the Q2 update could have a marginal impact on the stock," they added.The company has more meaningful near-term upside from the expected approval and launch of Ziihera in GEA, with a PDUFA date of Aug. 25, according to the note.Longer term, additional value creation is expected from business development and pipeline expansion, as well as breast cancer topline data expected in late 2027 to early 2028. "Despite some erosion to the sleep franchise (generics), we believe the base business should remain stable as we approach GEA's launch," the analysts said.The analysts expect Q2 total revenue of $1.1 billion, broadly in line with consensus, and full-year 2026 revenue of $4.4 billion versus consensus of $4.5 billion. Q2 earnings per share are expected to be $6.29 versus the consensus of $6.19 and the prior estimate of $6.49.UBS has a buy rating and a $307 price target on Jazz Pharmaceuticals.Price: $241.42, Change: $+3.91, Percent Change: +1.65%

$JAZZ
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Rates Announcement

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.7% in Wednesday's premarket activity, ahead of the highly anticipated interest rate announcement by the Federal Reserve at 2 pm ET.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.1%, and Nasdaq futures gaining 0.6% before the start of regular trading.Mortgage applications fell by 3.8% in the week ended June 12 after a 10.8% increase in the previous week, as average 30-year fixed mortgage rates held steady, according to Mortgage Bankers Association data released Wednesday.US retail sales rose by 0.9% in May, a larger gain than the 0.6% increase expected in a survey compiled by Bloomberg as of 7:35 am ET and following the previous month's revised 0.4% gain.The pending home sales data for May and the business inventories data for April are both scheduled to be released at 10:00 am ET.Weekly petroleum stocks data are due to be released at 10:30 am ET.The Federal Reserve's 2 pm ET announcement will be followed by new Fed Chair Kevin Warsh's first press conference at 2:30 pm ET.In premarket action, bitcoin was down by 1.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.2% lower, Ether ETF (EETH) retreated by 2.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was inactive.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.1%. The Vanguard Health Care Index Fund (VHT) fell 0.2% and the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was 0.5% higher.AbCellera Biologics (ABCL) shares rose 2.4%, and Jazz Pharmaceuticals (JAZZ) stock was up 1.6% premarket after the companies signed a preclinical research collaboration, option, and license deal to discover and develop T-cell-engaging multispecific antibodies.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.3%, the Vanguard Industrials Index Fund (VIS) was up 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.SpaceX (SPCX) stock was up more than 3% before the opening bell, following a 4.8% rise in Tuesday's session. Investor Michael Burry, known for calling the US housing collapse and the 2008 financial crisis, wrote in his newsletter on Tuesday that the company's put options remain too expensive.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 1.3%, and the iShares US Technology ETF (IYW) was up 0.8%, while the iShares Expanded Tech Sector ETF (IGM) was up 1.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.9% higher, while the iShares Semiconductor ETF (SOXX) rose by 2.7%.Nokia (NOK) shares were up 2.6% in premarket activity after the company said it will expand its advanced semiconductor test and packaging facilities in Allentown, Pennsylvania, to increase the manufacturing of photonic chips for artificial intelligence networks.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.6%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 1%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Stellantis (STLA) shares were up 1.9% pre-bell after Bloomberg reported, citing FIM-CISL labor union secretary general Ferdinando Uliano, that the company has pledged new investments in Italy, including 5 billion euros ($5.80 billion) in research and development by 2030 and the addition of engineering jobs.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.03%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% higher.Aegon (AEG) shares were down 0.8% pre-bell after gaining 1.5% at the prior close. The company said it has appointed Will Fuller as chief operating officer, effective Jan. 1, 2027.EnergyThe iShares US Energy ETF (IYE) was down 0.8%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.1%.YPF (YPF) stock was down 0.1% before the opening bell, adding to the 2.6% loss at the previous close. Reuters reported that the company signed a letter of intent to explore collaborations in fast-charging networks and energy storage infrastructure.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to $76.73 per barrel on the New York Mercantile Exchange. Natural gas retreated by 0.7% to $3.22 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 0.4%, while the United States Natural Gas Fund (UNG) was 1.1% lower.Gold futures for July were slightly lower to $4,352.50 an ounce on the Comex. Silver futures gained 0.1% to $70.58 an ounce. SPDR Gold Shares (GLD) declined by 0.01%, and the iShares Silver Trust (SLV) was 0.3% lower.

Dow JonesNasdaq CompositeS&P 500$ABCL$AEG$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$JAZZ$NOK$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$STLA$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD$YPF
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Shares of Novo Nordisk were up more than 3% pre-bell.uniQure (QURE) stock was up more than 66% after the company said it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Jazz Pharmaceuticals (JAZZ) and AbCellera Biologics (ABCL) signed a preclinical research collaboration, option and license deal to discover and develop T-cell engaging multispecific antibodies, the companies said. Shares of AbCellera Biologics were up more than 2% and Jazz Pharmaceuticals stock was over 1% higher premarket.

$ABCL$IBB$JAZZ$NVO$QURE$XLP
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks edged lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.3% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped 6%.Cogent Biosciences (COGT) said Bezuclastinib showed "rapid and deep" clinical benefit in advanced systemic mastocytosis patientsfollowing detailed and updated trial results. Shares rose 1.6%.

$AVTX$COGT$JAZZ
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.6% after it said Friday that a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet the primary overall survival endpoint, whether used alone or in combination with irinotecan, versus the investigator's choice of chemotherapy.

$JAZZ
Wire

BofA Securities Raises Price Target on Jazz Pharmaceuticals to $307 From $281, Maintains Buy Rating

Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $259.28, according to analysts polled by FactSet.(covers e281quity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $234.28, Change: $+5.09, Percent Change: +2.22%

$JAZZ
Research

Bernstein Initiates Coverage on Jazz Pharmaceuticals With Market Perform Rating

Jazz Pharmaceuticals Public Company (JAZZ) has an average rating of overweight and mean price target of $256.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$JAZZ
Research

UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $307 From $188

Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $245.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$JAZZ
Wire

Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC Says

Jazz Pharmaceuticals (JAZZ) delivered a "strong" Q1 as broad-based growth across its commercial portfolio and pipeline reinforced confidence in the health of the business, RBC Capital Markets said in a report Wednesday.Q1 revenue of about $1.07 billion topped the consensus estimate of $978 million, driven by strength across nearly "all major assets," the report said, adding that the company maintained its 2026 revenue guidance of $4.25 billion to $4.5 billion, though results could exceed that range.Concerns remain around future generic competition for the "oxybate franchise" and competitive pressures in oncology, though the firm believes the company's strong execution provides a cushion against potential "erosion." RBC estimates 2026 sales for Xywav at about $1.73 billion with expected "gradual decline" in later years, according to the report.The report also highlighted the company's "oncology pipeline" as a key focus, citing potential expansion opportunities for Ziihera, strong "initial uptake" for Modeyso, better-than-expected Zepzelca revenue and 15% year-over-year Epidiolex sales growth to $250 million driven by sustained epilepsy-related demand and international expansion.RBC maintained an outperform rating on Jazz Pharmaceuticals and raised its price target to $258 from $195.Price: $223.80, Change: $+11.54, Percent Change: +5.44%

$JAZZ
Insider Trading

Jazz Pharmaceuticals Insider Sold Shares Worth $1,219,980, According to a Recent SEC Filing

Bruce C Cozadd, Director, on May 01, 2026, sold 6,000 shares in Jazz Pharmaceuticals (JAZZ) for $1,219,980. Following the Form 4 filing with the SEC, Cozadd has control over a total of 378,682 ordinary shares of the company, with 378,682 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1232524/000119321026000011/xslF345X05/edgardoc.xml

$JAZZ

Track with the FINWIRES app suite

JAZZ News | FINWIRES